CD274 and neoplasm: We have previously demonstrated that CAN-2409, when added to anti-PD(L)1 antibody treatment, extends survival in preclinical tumor models (7) and changes the trajectory of tumor growth and reinvigorates the antitumoral response in patients inadequately responding to anti-PD(L)1 alone (21, 22).